In 540 newly-diagnosed AML patients treated with venetoclax plus a hypomethylating agent at Mayo Clinic, this retrospective study compared outcomes across four venetoclax cycle-1 durations (7, 14, 21, and 28 days), stratified by ELN 2024 and Mayo genetic risk groups, over a median follow-up of 37.7 months.
Transplant-censored median survival did not differ significantly across venetoclax durations (13.3, 11.9, 16.8, and 13.2 months for 7-, 14-, 21-, and 28-day, respectively; p=0.65); prognosis was driven by ELN risk (6.3 vs. 11.5 vs. 18.3 months for high, intermediate, low; p<0.01) and Mayo genetic risk (6.9 vs. 17.8 months vs. not reached; p<0.01). Among ELN high-risk patients, 14-day venetoclax was associated with inferior transplant-censored survival vs. 21- and 28-day schedules (p<0.01).
Retrospective single-center design with likely treatment selection bias — shorter venetoclax schedules had higher 30- and 60-day mortality (7-day: 9%/18%; 14-day: 7%/15% vs. 28-day: 2%/6%), suggesting sicker patients were assigned shorter durations. Allogeneic stem cell transplant rates were similar across groups (~15–20%), limiting power to detect transplant-driven survival differences.
Venetoclax duration alone (7 to 28 days) does not appear to be the primary driver of survival in newly-diagnosed AML; clinicians should weight ELN 2024 and Mayo genetic risk more heavily when counseling patients, though prospective risk-adapted trials are needed before shortening venetoclax cycles below 28 days — especially in ELN high-risk disease.